The global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market will grow by US$ 3.15 Billion by 2028 at a CAGR of 9.2% in the given forecast period.
The epidermal growth factor receptor (EGFR) is a protein-coding gene. It is found in high levels on cancer cells and is known to be responsible for the uncontrolled cell growth Inhibiting or blocking the growth of EGFR can stop the growth of cancer cells for long durations of time.
This rising occurrence of cancer can be attributed to factors such as increasing geriatric population and changing lifestyle. The increasing special drug designations and the high efficacy of EGFR inhibitors in the treatment of cancer indications such as lung cancer, colorectal cancer, and breast cancer will result in quicker approval during the clinical stages. Thus, the strong prevalence of major cancer indications will be a significant factor driving epidermal growth factor receptor inhibitors market.
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market is segregated on the basis of Type as Lung Cancer, Colorectal Cancer, Breast Cancer, and Others. Based on Application the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market is segmented in Hospital, Research Institutes and Institutions, Clinic, and Other.
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Epidermal Growth Factor Receptor (EGFR) Inhibitor market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis AG, and others are among the major players in the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Market has been segmented as below:
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Type
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Application
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Region
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Company
The report covers:
Report Scope:
The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market share. Major industry players with significant revenue share include Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis AG, and others.
Reasons to Buy this Report:
Customization
Customized report as per the requirement can be offered with appropriate recommendations.
Below are our New Reports :-
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach – Segmental Market Analysis
2.5.2 Top-Down Approach – Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter’s Five Force Analysis
5. Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Type
5.1 Introduction
5.2 Lung Cancer
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Colorectal Cancer
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Breast Cancer
5.4.1 Market Overview
5.4.2 Market Size and Forecast
5.5 Others
5.5.1 Market Overview
5.5.2 Market Size and Forecast
6. Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Application
6.1 Introduction
6.2 Hospital
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Research Institutes and Institutions
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Clinic
6.4.1 Market Overview
6.4.2 Market Size and Forecast
6.5 Other
6.5.1 Market Overview
6.5.2 Market Size and Forecast
7. Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Type
7.2.2 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Application
7.3 Europe
7.3.1 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Type
7.3.2 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Application
7.4 Asia-Pacific
7.4.1 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Type
7.4.2 Asia-Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Application
7.5 Rest of the World
7.5.1 Rest of the World Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Type
7.5.2 Rest of the World Epidermal Growth Factor Receptor (EGFR) Inhibitor, By Application
8. Competitive Insights
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
9. Company Profiles
9.1 Amgen Inc.
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 AstraZeneca Plc
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 Eli Lilly and Co.
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 F. Hoffmann-La Roche Ltd.
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
9.5 Novartis AG
9.5.1 Company Overview
9.5.2 Product/Service Landscape
9.5.3 Financial Overview
9.5.4 Recent Developments
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Market has been segmented as below:
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Type
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Application
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Region
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market, By Company
